UCM-1306 is an orally bioavailable positive allosteric modulator (PAM) of the dopamine D1 receptor. It enhances the maximal efficacy of endogenous dopamine and has demonstrated potential in preclinical research for improving both motor and cognitive deficits associated with Parkinsons disease models.